3.64
Absci Corp Aktie (ABSI) Neueste Nachrichten
Absci (NASDAQ:ABSI) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Absci’s ABS-201 stimulates human hair follicle growth ex vivo - BioWorld MedTech
Absci’s ABS-201 antibody shows promise for hair regrowth treatment - Investing.com
Absci’s ABS-201 antibody shows promise for hair regrowth treatment By Investing.com - Investing.com Canada
Absci Reports New Human Ex Vivo Data Demonstrating That - GlobeNewswire
Is Absci Poised for a Surge? - StocksToTrade
Absci, former U.S. soccer player Donovan announce partnership - TipRanks
Absci Corporation Partners with Landon Donovan to Address Androgenetic Alopecia and Advance Therapeutic Innovations - Quiver Quantitative
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewswire
Absci (NASDAQ:ABSI) Transforms Biotechnology With AI Integration - Kalkine Media
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine? - simplywall.st
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - The Globe and Mail
Absci (NASDAQ:ABSI) Stock Price Up 10.8%Still a Buy? - MarketBeat
Absci doses first volunteers in phase 1/2a trial of hair loss antibody - Investing.com Nigeria
Absci doses first volunteers in phase 1/2a trial of hair loss antibody By Investing.com - Investing.com South Africa
Absci Stock’s Financial Prospects: An In-Depth Analysis - StocksToTrade
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial - simplywall.st
Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com
Absci announces first participants dosed in Phase 1/2a HEADLINE trial - TipRanks
Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance
Absci Announces First Participants Dosed In Phase 1/2A Headline Trial - TradingView
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - The Manila Times
Will Absci Corporation stock deliver shareholder valueJuly 2025 Opening Moves & AI Optimized Trade Strategies - Newser
Absci stock price target raised to $9 from $8 at Jones Trading By Investing.com - Investing.com South Africa
Absci stock price target raised to $9 from $8 at Jones Trading - Investing.com Canada
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $9 - 富途牛牛
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci Corp. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Will Absci Corporation see short term momentumWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
How Absci Corporation stock benefits from tech adoptionJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - newser.com
Can trapped investors hope for a rebound in Absci CorporationGlobal Markets & Community Shared Stock Ideas - newser.com
Can Absci Corporation stock double in next 5 yearsMarket Growth Report & Expert Approved Momentum Trade Ideas - newser.com
Will Absci Corporation stock maintain growth storyJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Absci Corp’s Earnings Call Highlights Strategic Growth - MSN
Can Absci Corporation stock deliver sustainable ROE2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Absci (ABSI) Valuation in Focus as Clinical Expansion and Partnership Efforts Gather Pace - Yahoo Finance
Can Absci Corporation stock surprise with earnings upsideJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Real time pattern detection on Absci Corporation stockPortfolio Update Summary & Proven Capital Preservation Methods - newser.com
Absci Corporation Advances AI-Driven Therapeutics - MSN
Absci’s Cash Reserves Bolster Future Financial Confidence - timothysykes.com
Absci Corporation (NASDAQ:ABSI) Q3 2025 Earnings Call Transcript - Insider Monkey
Absci Stock Takes a Leap: What’s Next? - StocksToTrade
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):